#fda-investigation

#fda-investigation

U.S. health officials are reportedly questioning the safety of several approved therapies to treat respiratory syncytial virus (RSV) in babies. The treatmentsspecifically, Sanofi and AstraZeneca's drug Beyfortus and Merck's drug Enflonsiaare shots that are given to infants in the first months of life to protect against complications from RSV, which is the number one cause of hospitalization in babies in the U.S. RSV typically hits in winter and can cause severe disease and even death in young babies and older adults.

The U.S. is in the grips of a botulism outbreak tied to a premium infant formula brand. At least 23 babies have been affected. All the reported cases of the paralyzing bacterial infection occurred between August and November and have been linked to powdered infant formula produced by ByHeart, according to a Food and Drug Administration report. The company voluntarily recalled all its products on November 11, and experts caution that more cases of the potentially fatal disease may surface.